409 related articles for article (PubMed ID: 25290810)
1. Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application.
Nnamani PO; Hansen S; Windbergs M; Lehr CM
Int J Pharm; 2014 Dec; 477(1-2):208-17. PubMed ID: 25290810
[TBL] [Abstract][Full Text] [Related]
2. A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers.
Pinto MF; Moura CC; Nunes C; Segundo MA; Costa Lima SA; Reis S
Int J Pharm; 2014 Dec; 477(1-2):519-26. PubMed ID: 25445970
[TBL] [Abstract][Full Text] [Related]
3. Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance.
Nnamani PO; Ugwu AA; Ibezim EC; Kenechukwu FC; Akpa PA; Ogbonna JN; Obitte NC; Odo AN; Windbergs M; Lehr CM; Attama AA
Int J Nanomedicine; 2016; 11():6365-6378. PubMed ID: 27932882
[TBL] [Abstract][Full Text] [Related]
4. Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation.
Han F; Yin R; Che X; Yuan J; Cui Y; Yin H; Li S
Int J Pharm; 2012 Dec; 439(1-2):349-57. PubMed ID: 22989987
[TBL] [Abstract][Full Text] [Related]
5. Ameliorating the in vivo antimalarial efficacy of artemether using nanostructured lipid carriers.
Vanka R; Kuppusamy G; Praveen Kumar S; Baruah UK; Karri VVSR; Pandey V; Babu PP
J Microencapsul; 2018 Mar; 35(2):121-136. PubMed ID: 29448884
[TBL] [Abstract][Full Text] [Related]
6. Nanostructured lipid carriers (NLC) based controlled release topical gel of clobetasol propionate: design and in vivo characterization.
Nagaich U; Gulati N
Drug Deliv Transl Res; 2016 Jun; 6(3):289-98. PubMed ID: 27072979
[TBL] [Abstract][Full Text] [Related]
7. Development of a quercetin-loaded nanostructured lipid carrier formulation for topical delivery.
Chen-yu G; Chun-fen Y; Qi-lu L; Qi T; Yan-wei X; Wei-na L; Guang-xi Z
Int J Pharm; 2012 Jul; 430(1-2):292-8. PubMed ID: 22486962
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery.
Noor NM; Sheikh K; Somavarapu S; Taylor KMG
Eur J Pharm Biopharm; 2017 Aug; 117():372-384. PubMed ID: 28412472
[TBL] [Abstract][Full Text] [Related]
9. Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity.
Parashar D; Aditya NP; Murthy RS
Drug Deliv; 2016; 23(1):123-9. PubMed ID: 24786480
[TBL] [Abstract][Full Text] [Related]
10. Targeted Nanostructured Lipid Carrier for Brain Delivery of Artemisinin: Design, Preparation, Characterization, Optimization and Cell Toxicity.
Emami J; Yousefian H; Sadeghi H
J Pharm Pharm Sci; 2018; 21(1s):225s-241s. PubMed ID: 30266137
[TBL] [Abstract][Full Text] [Related]
11. Nanostructured lipid carriers of artemether-lumefantrine combination for intravenous therapy of cerebral malaria.
Prabhu P; Suryavanshi S; Pathak S; Patra A; Sharma S; Patravale V
Int J Pharm; 2016 Nov; 513(1-2):504-517. PubMed ID: 27596113
[TBL] [Abstract][Full Text] [Related]
12. Nanostructured lipid carriers as semisolid topical delivery formulations for diflucortolone valerate.
Abdel-Salam FS; Mahmoud AA; Ammar HO; Elkheshen SA
J Liposome Res; 2017 Mar; 27(1):41-55. PubMed ID: 26956098
[TBL] [Abstract][Full Text] [Related]
13. Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis.
Pradhan M; Singh D; Murthy SN; Singh MR
Steroids; 2015 Sep; 101():56-63. PubMed ID: 26049018
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of arteether-loaded nanostructured lipid carriers for the treatment of malaria.
Ali Z; Mishra N; Baldi A
Artif Cells Nanomed Biotechnol; 2016; 44(2):545-9. PubMed ID: 25340261
[TBL] [Abstract][Full Text] [Related]
15. Topical Nanostructured Lipid Carrier Based Hydrogel of Mometasone Furoate for the Treatment of Psoriasis.
Kaur N; Sharma K; Bedi N
Pharm Nanotechnol; 2018; 6(2):133-143. PubMed ID: 29788899
[TBL] [Abstract][Full Text] [Related]
16. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery.
Gonzalez-Mira E; Egea MA; Souto EB; Calpena AC; García ML
Nanotechnology; 2011 Jan; 22(4):045101. PubMed ID: 21169662
[TBL] [Abstract][Full Text] [Related]
17. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject.
Joshi M; Pathak S; Sharma S; Patravale V
Int J Pharm; 2008 Nov; 364(1):119-26. PubMed ID: 18765274
[TBL] [Abstract][Full Text] [Related]
18. Impact of nanostructured lipid carriers on dapsone delivery to the skin: in vitro and in vivo studies.
Elmowafy M; Shalaby K; Ali HM; Alruwaili NK; Salama A; Ibrahim MF; Akl MA; Ahmed TA
Int J Pharm; 2019 Dec; 572():118781. PubMed ID: 31715347
[TBL] [Abstract][Full Text] [Related]
19. Optimization of artemether-loaded NLC for intranasal delivery using central composite design.
Jain K; Sood S; Gowthamarajan K
Drug Deliv; 2015; 22(7):940-54. PubMed ID: 24512368
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of Nanostructured Lipid Carriers Loaded Chitosan/ Carbopol Hybrid Nanocomposite Gel for Oral Delivery of Artemether and Curcumin.
Kumar A; Behl T; Uniyal T; Chadha S
Pharm Nanotechnol; 2020; 8(5):418-432. PubMed ID: 32895049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
